High dose Ara-C

ApprovedSmall molecule

High dose Ara-C is one of 8 small molecule programs targeting Adult Acute Myeloid Leukemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adult Acute Myeloid LeukemiaActive, not recruiting

Adult Acute Myeloid LeukemiaApproved

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Adult Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Cytosar

Teva

Approved

1 2

Revuforj

SSyndax Pharmaceuticals

Approved

—3

Standard Dose ARA-C

NNational Research Center for Hematology, Russia

Approved

1 4

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 5

High dose Ara-C

PProf. Dr. M. Dreyling (co-chairman)

Approved

1 6

Ara-C

KKaryopharm Therapeutics Inc

Phase 2

1 7

Venclexta

AbbVie

Preclinical

—8

Cerubidine

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Relapsed or Refractory1 trial

Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL

Unknown status·PProf. Dr. M. Dreyling (co-chairman)·Phase 3·NCT01449344·128 enrolled

Adult Acute Myeloid Leukemia1 trial

3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia

Unknown status·NNational Research Center for Hematology, Russia·Phase 4·NCT01587430·245 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for High dose Ara-C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — High dose Ara-C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for High dose Ara-C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Prof. Dr. M. Dreyling (co-chairman) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PProf. Dr. M. Dreyling (co-chairman)

High dose Ara-C

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Relapsed or Refractory1 trial

Adult Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News